autologous anti-CD19 AbTCR-expressing T lymphocytes EB103

{
  "id": "MLC-T-ONC-011352",
  "term": "autologous anti-CD19 AbTCR-expressing T lymphocytes EB103",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes transduced with a lentiviral vector encoding an antibody-T-cell-receptor (AbTCR) composed of a CD19-binding domain derived from an antibody fragment antigen binding (Fab) region and an effector domain derived from human gamma/delta TCR, and a co-stimulatory molecule composed of a CD19-binding domain derived from a single-chain variable fragment (scFv) and a co-stimulatory domain derived from a human co-stimulatory receptor, with potential immunostimulating and antineoplastic activities. Upon administration of the autologous anti-CD19 AbTCR-expressing T lymphocytes EB103, both the AbTCR moiety and the co-stimulatory molecule recognize and bind to CD-19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies.",
  "synonyms": [
    "autologous anti-CD19 AbTCR-expressing T cells EB103",
    "autologous anti-CD19 antibody redirected T cells with endogenous modular immune signaling EB103",
    "autologous CD19-redirected ARTEMIS T cells EB103"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cd19-abtcr-expressing-t-lymphocytes-eb103/"
}